Article ID Journal Published Year Pages File Type
8536862 Pharmacology & Therapeutics 2018 29 Pages PDF
Abstract
Despite advances in neurosurgical techniques and radio-/chemotherapy, the treatment of brain tumors remains a challenge. This is particularly true for the most frequent and fatal adult brain tumor, glioblastoma (GB). Upon diagnosis, the average survival time of GB patients remains only approximately 15 months. The alkylating drug temozolomide (TMZ) is routinely used in brain tumor patients and induces apoptosis, autophagy and unfolded protein response (UPR). Here, we review these cellular mechanisms and their contributions to TMZ chemoresistance in brain tumors, with a particular emphasis on TMZ chemoresistance in glioma stem cells and GB.
Keywords
Related Topics
Health Sciences Pharmacology, Toxicology and Pharmaceutical Science Pharmacology
Authors
, , , , , , , , , , , , , ,